Skip to main content

Zusammenfassung

Gicht ist eine Stoffwechselkrankheit mit erhöhten Harnsäurespiegeln im Serum, die durch erhöhte hepatische Bildung (selten) oder renale Minderausscheidung (häufig) bedingt ist. Die Hyperurikämie ist zunächst oft symptomlos. Gichtkomplikationen entstehen durch kristalline Ausfällung der Harnsäure. In der Synovia von Gelenken führt dies zu schmerzhaften Gichtanfällen, im Gewebe zu immunologischer Reaktion mit Knötchenbildung (Tophi), in der Niere zu Uratsteinen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Dalbeth N, Merriman TR, Stamp LK (2016): Gout. Lancet 388: 2039–2052

    Google Scholar 

  • Fachinformation Zyloric (2016): https://www.fachinfo.de/suche/fi/002332

  • Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, tonelli M (2013): A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43: 367–375

    Google Scholar 

  • Janssens H, Lucassen P, Van de Laar F, Janssen M, Van de Lisdonk E (2008): Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008 Apr 16; (2): CD005521

    Google Scholar 

  • Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology (2012): 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 64: 1447–1461

    Google Scholar 

  • Lin KC, Lin HY, Chou P (2000): Community based epidemiological study on hyperuricemia and gout in Kin-Hou. J Rheumatol 27: 1045–1050

    Google Scholar 

  • Löffler W, Simmonds HA, Gröbner W (1983): Gout and uric acid nephropathy: Some new aspects in diagnosis and treatment. Klin Wochenschr 61: 1223–1239

    Google Scholar 

  • Love BL, Barrons R, Veverka A, Snider KM (2010): Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy 30: 594–608

    Google Scholar 

  • NN (2014): Bei asymptomatischer Hyperurikämie wird zu häufig Allopurinol verordnet. Arzneimittelbrief 48: 46–47

    Google Scholar 

  • Pasina L, Brucato AL, Djade CD, Di Corato P, Ghindoni S, Tettamanti M, Franchi C, Salerno F, Corrao S, Marcucci M, Mannucci PM, Nobili A (2014): Inapprobiate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry. Eur J Clin Pharmacol 70: 1495−1503

    Google Scholar 

  • Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017): 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76: 29–42

    Google Scholar 

  • Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK (2017): Serum uric acid and the risk of incident and recurrent gout: A systematic review. J Rheumatol 44: 388–396

    Google Scholar 

  • Sundy JS (2010): Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 22: 188–193

    Google Scholar 

  • Suresh E, Das P (2012): Recent advances in management of gout. QJM 105: 407–417

    Google Scholar 

  • Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012): Febuxostat for treating chronic gout. Cochrane Database Syst Rev. 2012 Nov 14; 11: CD008653

    Google Scholar 

  • Van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D (2014): Colchicine for acute gout. Cochrane Database Syst Rev Issue 8: CD006190

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bernd Mühlbauer .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Germany

About this chapter

Cite this chapter

Mühlbauer, B., Schmidt, G. (2017). Gichtmittel. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54630-7_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54629-1

  • Online ISBN: 978-3-662-54630-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics